Ampio Pharma to Study Ampion in COVID-19 Induced ARDS

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company focused on the development of immunology based therapies, was featured on a FOX segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver, Colorado. The primary cause of death associated with SARS-Cov-2 (COVID-19) infection is Acute Respiratory Distress Syndrome (ARDS), and there are no approved treatments for ARDS or COVID-19. The segment featured the Company's application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.

Michael Macaluso, Ampio CEO, said, "The Company is exploring options that may enable the completion of the AP-013 study, our Phase 3 clinical trial for the treatment of severe osteoarthritis of the knee, during this COVID-19 pandemic. Simultaneously, we have directed our R&D efforts to explore the possible application of the immunomodulatory and anti-inflammatory properties of Ampion in the most severe and lethal complication of the COVID-19 infected patients: ARDS. The FDA has been very responsive, and the Company is grateful for the Agency's efforts as we work together to study the potential benefits of Ampion in this population."

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.